牛熊異動 | 售出認股權,阿裏健康認購證漲50%
阿里健康(00241.HK)盤中持續上漲,相關衍生品里康法興零十購B(29663.HK)漲幅超50%。
消息面上,阿里健康發佈公告,於2020年9月15日,公司根據股份獎勵計劃的條款向一名承授人授出11.9萬份認股權,已授出認股權的行使價爲每股股份18.66港元,認股權的有效期爲由授出日期起計十年,而認股權將於有效期屆滿時失效。於2020年9月15日,公司根據股份獎勵計劃的條款向127名承授人授出425.95萬股受限制股份單位,將授予承授人的各受限制股份單位賦有權利可於其歸屬日期收取一股股份;及授出的受限制股份單位不受表現目標所限。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.